Page 5 - Marie Fields News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail New York City, January 6, 2021 - CytoDel, Inc. ("CytoDel" or "the Company"), a privately-held corporation, today announces the publication of preclinical data on the Company's lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. The complete text of the article titled, "Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism," can be found here. Cyto-111 was conceived, expressed and purified in the laboratory of Konstantin Ichtchenko, Ph.D., NYU Grossman School of Medicine, Department of Biochemistry and Molecular Pharmac...

Share this article Share this article LUND, Sweden, Dec. 23, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's management team will present at the 39th Annual J.P. Morgan Healthcare Conference 2021. The company presentation will take place virtually Thursday January 14, 2021 at 7:30 am (EST)/13:30 (CET).  Management will outline Hansa Biopharma's proprietary enzyme technology platform as well as provide a status update on Idefirix ® (imlifidase), which recently obtained conditional approv...